NCT01204957

Brief Summary

Japanese postmenopausal women in Japan have about one ninth the rate of American postmenopausal women. Rates of breast cancer double even after just ten years among Japanese women who migrate to the US. Diet is thought to be an important factor, and the investigators were interested in whether dietary seaweed, with and without soy supplements, could influence known biomarkers of breast cancer risk in American women.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
33

participants targeted

Target at P25-P50 for phase_1 breast-cancer

Timeline
Completed

Started Oct 1998

Shorter than P25 for phase_1 breast-cancer

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 1998

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 1999

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 1999

Completed
11.6 years until next milestone

First Submitted

Initial submission to the registry

September 16, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 17, 2010

Completed
Last Updated

April 6, 2015

Status Verified

April 1, 2015

Enrollment Period

5 months

First QC Date

September 16, 2010

Last Update Submit

April 2, 2015

Conditions

Keywords

HomocysteineInsulin-like growth factorInsulin-like growth factor binding proteinSerum estrogenUrinary phytoestrogensThyroid hormones

Outcome Measures

Primary Outcomes (1)

  • Thyroid hormones affected by dietary seaweed and soy supplements

    6 wk seaweed followed by 1 wk seaweed plus soy; Or 6 wk placebo followed by 1 wk soy 3 wk washout period then crossover to alternate arm

    14 weeks

Secondary Outcomes (3)

  • Serum estrogen and urinary phytoestrogen concentrations affected by seaweed and soy

    14 wks

  • Serum antioxidant and homocysteine concentrations associated with seaweed and soy

    14 wks

  • Serum IGF-1 and IGFBP3 changes associated with seaweed and soy supplementation

    14 wk

Study Arms (2)

Arm 1 Seaweed and Soy Protein

EXPERIMENTAL

Arm 1 5 g/d Seaweed for 6 wk, then 5 g/d Seaweed and Soy Protein for 1 wk

Dietary Supplement: Seaweed and Soy Protein

Arm 2 Placebo and soy protein

EXPERIMENTAL

Arm 2 5 g/d Placebo for 6 wk, then 5 g/d Placebo and Soy Protein for 1 wk

Dietary Supplement: Placebo and Soy Protein

Interventions

Seaweed and Soy ProteinDIETARY_SUPPLEMENT

5 g/d Seaweed for 6 wks, followed by 5 g/d Seaweed + Soy Protein for 1 wk

Also known as: Solae Soy Food Ingredient Powder (AB1.2 HG 20CA 29), Alaria esculenta
Arm 1 Seaweed and Soy Protein
Placebo and Soy ProteinDIETARY_SUPPLEMENT

5 g/d Placebo for 6 wks, followed by 5 g/d Placebo + Soy Protein for 1 wk

Also known as: Solae Nutritious Food Ingredient Powder (AB1.2 HG 20CA 29), Maltrin M100 maltodextrin (Grain Processing)
Arm 2 Placebo and soy protein

Eligibility Criteria

Age18 Years - 80 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Postmenopausal (self-reported cessation of menstruation 1 y prior to enrollment)
  • If breast cancer survivor, all therapy completed at least 6 months prior to enrollment
  • Agreed to eat their normal diet, avoiding seaweeds and phytoestrogen-rich foods,
  • Restricting alcoholic intake to #2 drinks (24 g alcohol)/wk -Continuing habitual intake of vitamins, supplements, and medications during the study. -

You may not qualify if:

  • No allergies to seaweed, soy, shellfish, or iodine
  • No current use of tobacco;
  • No thyroid dysfunction or treatment within the previous 5 y;
  • Negative thyroid peroxidase antibodies as determined by screening;
  • No hormone replacement therapy or for breast cancer survivors, no chemotherapy or radiation treatments within the preceding 6 mo
  • No history of cancer (other than breast cancer)
  • No current gastrointestinal disorders or diabetes; omnivorous eating habits, including meat and dairy products at least twice/wk
  • No oral antibiotics, iodine containing medications, or corticosteroids treatment within the previous 3 mo.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Massachusetts

Worcester, Massachusetts, 01655, United States

Location

Related Publications (3)

  • Teas J, Hurley TG, Hebert JR, Franke AA, Sepkovic DW, Kurzer MS. Dietary seaweed modifies estrogen and phytoestrogen metabolism in healthy postmenopausal women. J Nutr. 2009 May;139(5):939-44. doi: 10.3945/jn.108.100834. Epub 2009 Mar 25.

  • Teas J, Braverman LE, Kurzer MS, Pino S, Hurley TG, Hebert JR. Seaweed and soy: companion foods in Asian cuisine and their effects on thyroid function in American women. J Med Food. 2007 Mar;10(1):90-100. doi: 10.1089/jmf.2005.056.

  • Teas J, Pino S, Critchley A, Braverman LE. Variability of iodine content in common commercially available edible seaweeds. Thyroid. 2004 Oct;14(10):836-41. doi: 10.1089/thy.2004.14.836.

MeSH Terms

Conditions

Breast Neoplasms

Interventions

Soybean Proteins

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Plant ProteinsProteinsAmino Acids, Peptides, and ProteinsPlant Proteins, DietaryDietary ProteinsFoodDiet, Food, and NutritionPhysiological PhenomenaSoy FoodsVegetable ProductsVegetablesFood and Beverages

Study Officials

  • Jane Teas, Ph.D.

    University of South Carolina

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

September 16, 2010

First Posted

September 17, 2010

Study Start

October 1, 1998

Primary Completion

March 1, 1999

Study Completion

March 1, 1999

Last Updated

April 6, 2015

Record last verified: 2015-04

Locations